How many clinical trials are studying Fruquintinib?

15 recruiting trials in our tracked data involve Fruquintinib.

What conditions is Fruquintinib being studied for?

In our tracked recruiting trials, Fruquintinib is being studied in trials for Colorectal Cancer, Metastatic Colorectal Cancer, Antineoplastic Agents, Immunological.

Fruquintinib: clinical trials recruiting now

Q: Is Fruquintinib FDA-approved?

Yes. According to the FDA drug label available through openFDA, Fruquintinib is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Fruquintinib appears in the FDA drug-label database. Marketed as Fruzaqla.

FDA-approved use

. INDICATIONS AND USAGE FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. ( 1 )

FDA label via openFDA

Phase breakdown

Phase 2 9 Phase 3 2 Phase 4 2 Not applicable 3

Conditions being studied

Condition	Trials
Colorectal Cancer · Fruquintinib for Colorectal Cancer	15
Metastatic Colorectal Cancer	2
Antineoplastic Agents, Immunological	1
Colon Cancer	1
Colorectal Cancer (CRC)	1
Colorectal Cancer Metastatic	1
MSS Metastatic Colorectal Cancer	1
Metastatic Colorectal Adenocarcinoma	1
Metastatic Colorectal Cancer (CRC)	1
Microsatellite Stable Colorectal Carcinoma	1
Rectal Cancer	1
VEGFR-TKI	1

Recruiting trials involving Fruquintinib

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
NCT06992258 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
NCT07011576 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
NCT06497985 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study
NCT05954429 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
NCT07235293 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
NCT06562543 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 45 locations
Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
NCT07130903 · Phase: Phase 2 · Ages: 22 Years and older · Sex: All (male and female) · 9 locations
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
NCT06551207 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
NCT06168786 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer
NCT06118762 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.
NCT06613113 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
NCT06441565 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer
NCT07124858 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 83 locations
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
NCT06685276 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
NCT05771181 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

Is Fruquintinib FDA-approved?

Yes, marketed as Fruzaqla.

How many recruiting trials involve Fruquintinib?

15 recruiting trials across 12 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.